Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes
Abstract Background Since national essential medicine lists guide the procurement of medicines for populations in many countries, and cardiovascular diseases are the leading cause of death globally, including cardiovascular medicines on these lists can significantly impact healthcare outcomes. Metho...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-024-04411-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571995199373312 |
|---|---|
| author | Camila Heredia Moizza Zia Ul Haq Adelaide Buadu Amal Rizvi Aine Workentin Navindra Persaud |
| author_facet | Camila Heredia Moizza Zia Ul Haq Adelaide Buadu Amal Rizvi Aine Workentin Navindra Persaud |
| author_sort | Camila Heredia |
| collection | DOAJ |
| description | Abstract Background Since national essential medicine lists guide the procurement of medicines for populations in many countries, and cardiovascular diseases are the leading cause of death globally, including cardiovascular medicines on these lists can significantly impact healthcare outcomes. Methods In this cross-sectional study, national essential medicines’ lists from 158 countries were analysed on whether or not they included medicines to treat ischemic heart disease, cerebrovascular disease, and hypertensive heart disease. A linear regression model was used to evaluate the association between countries’ coverage scores and amenable mortality. Results Listing of cardiovascular disease treatment was associated with amenable mortality from hypertensive heart disease. Health expenditure per capita was also associated with amendable mortality due to ischemic heart disease, and hypertensive heart disease. Conclusions Listing essential medicines for cardiovascular disease is an important aspect of healthcare quality that is associated with cardiovascular mortality. |
| format | Article |
| id | doaj-art-498d0cc9806d4b569396b25ad3f125e8 |
| institution | Kabale University |
| issn | 1471-2261 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj-art-498d0cc9806d4b569396b25ad3f125e82025-02-02T12:07:45ZengBMCBMC Cardiovascular Disorders1471-22612025-01-0125111110.1186/s12872-024-04411-yCardiovascular disease essential medicines listing by countries: changes over time and association with health outcomesCamila Heredia0Moizza Zia Ul Haq1Adelaide Buadu2Amal Rizvi3Aine Workentin4Navindra Persaud5MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health TorontoMAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health TorontoMAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health TorontoMAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health TorontoMAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health TorontoMAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health TorontoAbstract Background Since national essential medicine lists guide the procurement of medicines for populations in many countries, and cardiovascular diseases are the leading cause of death globally, including cardiovascular medicines on these lists can significantly impact healthcare outcomes. Methods In this cross-sectional study, national essential medicines’ lists from 158 countries were analysed on whether or not they included medicines to treat ischemic heart disease, cerebrovascular disease, and hypertensive heart disease. A linear regression model was used to evaluate the association between countries’ coverage scores and amenable mortality. Results Listing of cardiovascular disease treatment was associated with amenable mortality from hypertensive heart disease. Health expenditure per capita was also associated with amendable mortality due to ischemic heart disease, and hypertensive heart disease. Conclusions Listing essential medicines for cardiovascular disease is an important aspect of healthcare quality that is associated with cardiovascular mortality.https://doi.org/10.1186/s12872-024-04411-yEssential medicinesCardiovascular diseaseIschemic heart diseaseCerebrovascular diseaseHypertensive heart diseaseAmenable mortality |
| spellingShingle | Camila Heredia Moizza Zia Ul Haq Adelaide Buadu Amal Rizvi Aine Workentin Navindra Persaud Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes BMC Cardiovascular Disorders Essential medicines Cardiovascular disease Ischemic heart disease Cerebrovascular disease Hypertensive heart disease Amenable mortality |
| title | Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes |
| title_full | Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes |
| title_fullStr | Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes |
| title_full_unstemmed | Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes |
| title_short | Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes |
| title_sort | cardiovascular disease essential medicines listing by countries changes over time and association with health outcomes |
| topic | Essential medicines Cardiovascular disease Ischemic heart disease Cerebrovascular disease Hypertensive heart disease Amenable mortality |
| url | https://doi.org/10.1186/s12872-024-04411-y |
| work_keys_str_mv | AT camilaheredia cardiovasculardiseaseessentialmedicineslistingbycountrieschangesovertimeandassociationwithhealthoutcomes AT moizzaziaulhaq cardiovasculardiseaseessentialmedicineslistingbycountrieschangesovertimeandassociationwithhealthoutcomes AT adelaidebuadu cardiovasculardiseaseessentialmedicineslistingbycountrieschangesovertimeandassociationwithhealthoutcomes AT amalrizvi cardiovasculardiseaseessentialmedicineslistingbycountrieschangesovertimeandassociationwithhealthoutcomes AT aineworkentin cardiovasculardiseaseessentialmedicineslistingbycountrieschangesovertimeandassociationwithhealthoutcomes AT navindrapersaud cardiovasculardiseaseessentialmedicineslistingbycountrieschangesovertimeandassociationwithhealthoutcomes |